Alpha-MSH vs PT-141

Alpha-MSH wins for broad melanocortin receptor coverage (MC1R–MC5R), natural physiology mimicry, and immune modulation potential. PT-141 wins for sexual arousal potency, PK stability (hours vs. minutes), real-world effectiveness for libido, slower but longer-lasting action, and practical community dosing protocols.

Pick Alpha-MSH if:

• The research goal is pan-melanocortin activation (multi-axis: pigmentation, appetite regulation, immune/inflammatory modulation).
• Modeling physiologic melanocortin signaling (as in animal or cellular studies) is required.
• Investigating short-acting endogenous peptides (minutes-scale PK) is desired.
• Testing receptor cross-talk effects (MC1R, MC3R, MC4R, MC5R all in play).
• Avoiding synthetic modifications is a priority.

Pick PT-141 if:

• The primary outcome is robust, reliable MC4R-driven sexual arousal and libido enhancement.
• Real-world dosing convenience and effective plasma half-life (2–4 h) are needed.
• Modeling PDE5 non-responder sexual function protocols (central > peripheral) is the endpoint.
• Sourcing/trusted dosing data from the bodybuilding and looksmaxxing community is important.
• Stacked administration with PDE5 inhibitors and/or dopamine agonists (cabergoline) is in scope.